ARCHIVES

Texas Oncology Designated Aranesp As Preferred Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 46 | December 13, 2002

Download PDF Visit The Full Archive

Related Articles

Upton Wraps Up Reorganization – DCCR Revamped, No Prevention Division

October 12, 1979

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

NCI Programs: Advisors Approve Plans For New Grants In Imaging Research

July 10, 1998

Oncology Management: US Oncology To Conduct Up To 5 Studies Of PG-TXL In Colorectal, Lung Cancers

June 1, 2001

Proteomics Used To Find Predictor Of Response In FAP

April 30, 2004

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003